Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001801917Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 BERMUDA HM11
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza - Floor 5 New York NY 10111	23622	259448.15	766811433	07/27/2023	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Amount of Title of the Name of Date you Nature of Is Date Date of Nature of Class Acquired Acquisition Person from this Donor Securities Payment Payment *

	Transaction	Whom Acquired	a Acquire Gift?	d Acquired	
Common	Options Exercise - 07/27/2023 Grant Date 4/20/2022	Roivant Sciences Ltd.		23622	07/27/2023 Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale Secu	ount of urities Gross Proceeds fold
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	04/27/2023 73514	625908.88
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	04/28/2023 75823	641877.24
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/01/2023 61155	525251.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/02/2023 109074	4 897477.32
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/03/2023 118760	0 997196.40
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/04/2023 88838	737504.16
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/08/2023 61206	546237.33
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/09/2023 23872	4 2204059.84
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/23/2023 15671	150128.18
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/23/2023 415	4087.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor	Common	06/07/2023 201	1979.85

50 Broadway London X0 SW1H 0DB Eric Venker c/o Roivant Sciences Ltd. 7th Floor	Common	06/09/2023 299384	2967299.96
50 Broadway London X0 SW1H 0DB			
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/22/2023 15882	158978.82
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	07/20/2023 159387	1802034.65
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	07/21/2023 181998	2025358.44
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	07/21/2023 28937	322068.81
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	07/24/2023 16297	179104.03
Eric Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	07/24/2023 33081	361645.23
Erick Venker C/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	07/25/2023 28344	307869.19
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	07/26/2023 73568	802811.91

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/25/2023.
Date of Notice	07/27/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/25/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Jason Coleman as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)